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Abstract
In this chapter, the authors review a major complication associated with cystic fibrosis
(CF), problematic bacterial infections of the lungs. Infection by organisms such as
Staphylococcus aureus, Burkholderia cepacia complex, and Pseudomonas aeruginosa (a
major player in CF related infections) results in complications due to increased
inflammation and production of virulence factors produced by the bacteria. In
addition to these more canonical organisms associated with CF infection, emerging‐
bacterial species have been found in the CF, including anaerobes that have only within
the past 5-10 years have been reported to exist in the lungs. P. aeruginosa has long been
a cause of devastating infections, and is often seen as the“hallmark”organism
associated with the disease. The authors describe the P. aeruginosa infection, including
its conversion to a mucoid phenotype, as well as its ability to utilize the thicker airway
surface layer associated with CF to grow in “mode two biofilms.” Finally, the authors
discuss treatments for bacterial infections, and some of the new advances that
offerhope for treatment of CF symptoms and infections by multi-drug resistant
organisms. Among these new treatments is the application of acidified nitrite, a non-
antibiotic treatment that has been found to be effective at killing nonmucoid and
mucoid variants of P. aeruginosa.
Keywords: Cystic Fibrosis, Infections, Bacteria, Pseudomonas aeruginosa, Biofilm,
Acidified Nitrite
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1. Introduction
Cystic fibrosis (CF) is the second most common genetic disease in the United States, second
only to sickle cell anemia. A mutation in the associated gene, cystic fibrosis transmembrane
regulator (CFTR), results in the clinical symptoms seen for the disease. While the disease itself
is devastating, it does not usually result in the immediate death of the patient. Rather, the
bodily conditions that the CFTR mutation creates, especially in the lungs, results in the
acquisition of problematic bacterial biofilm infections that remain in the thick, inspissated
mucus layer for the remainder of the patient’s life. This unique niche provides many complex
nutrients that the bacteria utilize and offers an environment that is protected against the host’s
innate immune system. While only a few bacterial species have generally been thought of as
dominating the CF lung, it has recently been revealed that there are many species inhabiting
the lung, and that these species vary from normal flora to even obligate anaerobes [1]. While
the exact role of all these bacterial species in the lung has not yet been determined, the clinical
picture is becoming clearer.
When the genetic cause of CF was first identified in 1989 [2], the average lifespan of a CF patient
was approximately 15 years of age. Since then, it has increased to roughly 40 [3, 4]. This is due
to the tremendous efforts that have been made in determining new and improved means of
treating patients suffering from CF, including addressing physiological parameters and
methods of treating bacterial infections.
This chapter will focus on the bacterial infections that develop during CF and the conditions
of the lung that make it so favorable for bacterial infection. We will discuss some of the major
bacterial species that contribute to the morbidity of the disease, and focus on perhaps the
largest contributor to airway infection, Pseudomonas aeruginosa (PA). In addition, we will define
some of the niches that the bacteria inhabit within the lung, and discuss treatment options for
infected individuals.
2. Overview of CF and the role of CFTR in the lung
2.1. CFTR: Role and function
The function of CFTR in the lungs has been established previously, supporting the fact that its
absence or modification (depending on the mutation) leads to the dangerous symptoms that
are diagnostic hallmarks in CF patients. Although some canonically think of CFTR as only
being influential in the development of the lung problems, CFTR is actually expressed in many
areas of the body, including the liver, intestines, pancreas, skin, and reproductive organs
(Figure 1). In all these cases, a defect in CFTR can cause many problems for the affected organ.
The reason is due to the large role the transporter plays in the maintenance of osmotically
balanced fluids in these tissues. CFTR is an anion channel found in the apical membrane of
epithelial cells, primarily responsible for pumping chloride ions into the fluids surrounding
the epithelial cells, and allowing for the passage of water from the epithelial cells into the fluid
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layers lining the cells (e.g, the pericilliary layer (PCL) of the airways) [5, 6, 7]. This allows the
fluids to maintain their function, which, in the lung, is usually to facilitate clearance of
opportunistic pathogens and cellular debris from the area or to transport the fluid to a different
area (as is the case in the reproductive system). The transporter itself is ATP-driven, and is
activated due to rising cAMP levels in the cells [7].
Figure 1. Organs affected by CF and its effect on airways.
A) An overview of the organs affected by CF, with a brief description of the complications
associated with it. B) A normal airway depicting open passages. C) A CF airway depicting the
buildup of mucus, inflammation, and bacterial infection that will lead to further complications.
(Source: National Heart, Lung, and Blood Institute; National Institutes of Health; U.S. Depart‐
ment of Health and Human Services. [8])
In cases where the CFTR is not active or only partially active, the consequences can be quite
severe. This is due to a myriad of potential mutations in the CFTR gene. These mutations have
been categorized into classes, as previously reviewed by Rowntree and Harris [9] and
summated by the Cystic Fibrosis Foundation. As shown in Table 1, these classes focus on the
means by which the CFTR is rendered dysfunctional, such as mutations affecting protein
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maturation (Class II) or those leading to dysregulation of Cl- conductance (Class IV) [9, 4]. The
most common mutation is a deletion of a phenylalanine residue at position 508 of the protein,
referred to as homozygous recessive ΔF508 [7]. Although the exact reasoning of why this
mutation was clinically deleterious was at first a mystery, it has come to be discovered that
this leads to a misfolding of the channel, causing it to never reach the cell membrane and
instead be destroyed in the Golgi apparatus. Although one could surmise that the loss of CFTR
alone is not enough to cause harm and the body could compensate for this loss by redundant
channels, it is also suspected that CFTR can help mediate the activation and use of other
channels in the membrane. Thus, its loss may be far more reaching than simply its anion
channeling properties. With this loss of function, the surrounding fluid begins to become
osmotically imbalanced and often viscous and impervious to other ions [6]. With no new water
coming into the fluids from the epithelial cells, the fluid layer begins to thicken, eventually
forming mucus plugs in the respective organ. As such, the associated ducts are no longer able
to perform their proper functions.
Table 1. Classifications of CFTR mutations and their impact on the protein.
Although there are numerous mutations that have been associated with CF, they can generally
be broken down into five classes based on the way this mutation affects CFTR. This table briefly
summarizes these classes and provides an example of each mutation [4].
2.2. The CF lung
Within the CF lung, the loss of functional CFTR is quite dramatic, and usually leads to the
canonical respiratory symptoms associated with CF lung disease. A healthy functioning lung
will have a thin, hydrated pericilliary mucus layer lining the airway. This mucus rests above
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the cilia of the epithelial cells in a biphasic layer [7]. The top layer is slightly more viscous than
the bottom layer and serves to trap bacteria and particles that enter the lung. The bottom layer,
referred to as the PCL, is much more fluid, and allows for the cilia to beat within it, pushing
the entire mucus layer up the lung for expectoration [7, 10]. Through this mechanism, the lungs
can clear bacteria and debris that has been inhaled or otherwise entered the airway passages.
The PCL is kept hydrated by the action of the CFTR and other ion channels present in the
epithelial cells lining the airway that also maintain the osmotic balance.
Figure 2. A model of the CFTR in the apical membrane of lung epithelia.
The CFTR, embedded in the apical membrane of epithelial cells, serves to transport anions,
specifically chloride and bicarbonate, into the lumen of the associated organ. The CFTR is
composed of several domains, including two transmembrane domains (red ovals), two
nucleotide binding domains (blue, squares), and a regulatory domain that controls the opening
of the transporter. The nucleotide binding domains use ATP to provide energy for the transport
of the anions into the lumen bordering the cell.
However, in a case such as CF, where the CFTR is functionally absent and proper ion transport
is lacking, the mucus layer begins to thicken. This is believed to be due to the primary transport
of Cl- [11, 6, 7] and the secondary transport of HCO3- by CFTR (Figure 2). Recent studies have
shown that the ability of CFTR to transport HCO3- is very important, as it seems to play a large
role in the regulation of the mucin folding [7]. Mucin, the primary protein component of airway
mucus, is a long chain-like, repetitive peptide that is heavily O- and N-glycosylated. At the C-
and N-terminal regions, the protein is rich in cysteine residues, which can lead to intermolec‐
ular disulfide bridges. These disulfide bridges will link the chains together, creating a larger
oligomer. It is suspected that in a more acidic environment, the mucin molecules contract,
causing the overall density of the mucus to increase. This causes impermeability issues [6] that
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can be devastating to the patient. In addition to the effects that decreased HCO3- levels have
on the density of the mucus, the general inability to transport anions across the apical mem‐
brane also affects the airway mucus layer. The PCL that lines the cilia of the epithelial cells is
very sensitive to changes in water concentration. When the cells are not exporting significant
amounts of ions, the PCL will then lose water as a sequela, resulting in it becoming denser and
reducing the effectiveness of ciliary beating. This leads to an overall larger amount of material
that cannot be cleared from the airway, causing a buildup or mucus plug.
In addition to the buildup of mucus as the disease progresses, the patient will experience
several other symptoms as well. Commonly, the bronchi become inflamed, caused by an
overreactive response from the immune system due to both mucus buildup (containing a
plethora of bacterial components such as virulence factors, DNA, and cell debris from lysed
bacteria or airway epithelial cells) and a potential infection. While the infections will be covered
in more detail later in this chapter, bacteria such as Pseudomonas aeruginosa (PA), H. influen‐
zae, and S. aureus have been found to infect CF patients early in life (roughly 1 year of age) [1],
and even if eradicated once, will often arise from a re-infection later in life. PA is the organism
most commonly associated with a decline in the clinical course of CF patients, as its ability to
form biofilms and convert to a mucoid phenotype often provides a large level of resistance to
antibiotics and other disease treatments.
Interestingly, the CF lung will also develop an oxygen gradient in its luminal mucus [12, 13].
As mentioned earlier, the increased density of the mucus makes it more difficult for oxygen
to diffuse across it freely and into the blood. While this has consequences for the overall health
of the individual, it also has implications for growth of bacteria enmeshed within it. The oxygen
gradient is severe enough that the basal layer of the mucus could be termed microaerobic, or
in more severe cases, anaerobic. This leads to the growth and development of bacteria that
would normally not be found in the lung, and eventually to the growth of the mucoid form of
PA. This will be covered in more depth later in this chapter.
2.3. Pathology of the CF lung
As might be expected, the buildup of thick mucus in the CF lungs often has severe clinical
implications The significant reduction or loss of mucus clearance often results in infection and
leads to inflammation due to the dramatic ~1,500-fold increase in airway neutrophils [14].
Coupling the inflammation and buildup of mucus, it is not surprising that the overall lung
capacity of CF patients decreases dramatically throughout life. This can be tested using a series
of pulmonary function tests (PFTs) [15]. These often involve a spirometry test, which is a
measure of the forced efflux volume in one second (FEV1), or how much air the patient can
forcefully exhale in one second. This is a hallmark test for overall lung volume and strength.
Clinically it has been shown that the FEV1 of a CF patient will be approximately 10% below
the expected for a healthy individual of the same age [16].
In older patients, the prolonged effects of the disease often lead to chronic infections. These
invading organisms can then be cultured and analyzed to determine the best treatment
strategy. While we will be covering the type of infections further in this chapter, it is important
to note that clinically, this also affects the patient in other ways, primarily leading to inflam‐
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mation of the respiratory system and decreased airway capacity [17]. This inflammation is
often brought on by increased neutrophil accumulation in the lungs, which not only serve to
act as a preliminary means of immune defense, but also to recruit macrophages. These
neutrophils and macrophages will phagocytose bacteria and dead immune cells, but also
produce pro-inflammatory cytokines that exacerbate the inflammatory process. These
cytokines not only attract other immune cells, but also serve as a trigger for the release of
proteases and elastases by the immune cells. Normally, these help eradicate the bacteria that
triggered this response, but theior over-production in the CF lung can actually damage
epithelial cells, leading to the fibrotic nature of cells associated with this disease [18].
3. Bacterial infections
While CF airway disease is based on the genetic mutation of the CFTR gene, this is not usually
what leads to the morbidity and mortality associated with the disease. Rather, an infectious
agent that grows under the physiological conditions created by this mutation will lead to
detrimental symptoms and eventual death. In the lungs, the buildup of thick mucus leads to
decreased clearance of bacteria and provides a nutrient rich medium with which they can grow
and even thrive. This mucus becomes colonized relatively easily with potentially several
different species of bacteria at once [19, 16, 20]. Considering that infection is the major source
of morbidity and mortality for CF patients, much research has focused on this aspect of the
disease and different means by which to eradicate it. However, time has shown that this is not
quite as easy as hoped, but the advancements of alternate treatments are helping this issue.
Bacterial colonization of the lungs of CF patients has been known for many decades. However,
our understanding of what bacteria colonize the lungs has evolved dramatically. Early
research identified that there were several species of bacteria that could colonize the lungs
easily, and were often found associated with CF patients. By far, the most common (and most
linked to severe progression of the disease) was PA. This gram-negative bacterium is often
considered an opportunistic pathogen, existing naturally in soil, water, and in some cases, as
part of the flora of human skin. However, in cases where the bacteria come into contact with
immune-deficient or severely compromised tissues, they can grow quite prolifically. A
common example is found with burn wounds, where PA can colonize the exposed flesh and
lead to the need for aggressive antibiotic treatment. This type of infection is often associated
with a distinct “smell of grapes” and the potential for a green-blue color to develop, indicative
of several of the toxins that PA produces such as the blue phenazine antibiotic, pyocyanin.
There are additional phenotypes that are seen with lung colonizing PA, the most dramatic of
which was found in 1964 by Doggett et al. [21]. In that work, the authors noted that the multiple
strains of PA that they could isolate on agar from CF patients all had a similar, mucoid
phenotype. Although, at the time, the significance of this was not known, this mucoid
phenotype is tightly linked to the overall progression of CF lung disease. It is indicative of the
organism’s ability to create a biofilm, a highly resistant matrix of exopolysaccharide and
bacteria that allows survival in harsh environments. We will cover the details of biofilms
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further into this chapter, but it is important to note the significance they play in CF disease
progression.
In addition to PA, three other major strains of bacteria were found associated with the CF lung.
The first of these is Staphylococcus aureus, a gram-positive organism that is part of the normal
skin flora. Often, S. aureus is found colonizing the nares of hosts, where it is hypothesized that
it can travel to the lungs. It is often the first bacterium identified in CF patients, potentially due
to a lack of proper immune defense within the newborns diagnosed with CF [22, 23]. It often
resides in the lungs for a prolonged period, although it can be eradicated with proper antibiotic
treatment. Similar to PA acquiring a mucoid variant, S. aureus can also acquire a different
phenotype. Small colony variants have been seen associated with lung cultures, which have
shown decreased expression of many of the virulence factors associated with S. aureus [24].
This could indicate that the bacteria are attempting to avoid the host immune system, allowing
survival in the lungs for a longer duration. What potentially worsens the overall clinical course
is the acquisition of MRSA in the lungs [23]. Although it is more rare than its antibiotic-sensitive
counterpart, it is possible to acquire this strain nosocomially, or even develop the strain
independently through the constant use of β-lactam antibiotics to treat existing,methicillin-
sensitive S. aureus (MSSA) infections. Interestingly, it has been found that in situations where
a patient is infected with both S. aureus and PA, treatment of one can lead to the prominence
of the other [25]. When patients were given anti-staphylococcal antibiotics, it was found that
PA infection could develop and fill the niche that the eradicated S. aureus no longer occupies.
This is another unfortunate side effect of a S. aureus infection, that not only can its treatment
lead to a potential development of MRSA but it can also cause an exacerbation of any existing
PA infection. This is of great clinical importance to note for younger patients who have not yet
been colonized with PA.
The second major strain historically found in addition to PA is Haemophilus influenzae. This
bacterium is similar to S. aureus in that it is a normal commensal organism of the nasopharynx
region, but can actually be found in normal lungs. As an individual progresses through life,
the chances of being colonized with H. influenzae increases, rising from 20% in infants, to 50%
of children, to more than 75% of adults [26]. This has led some to believe that H. influenzae is
one of the earliest CF pathogens, and that it modifies the lung in a manner that allows for
subsequent PA infection [27]. The forms of H. influenzae that can colonize an individual vary,
depending on the presence or absence of a capsule around the bacterium. When a capsule is
absent, the bacterium is referred to as non-typeable H. influenzae (NTHi), and this form is most
associated with respiratory infections [26]. Within the CF lungs, the bacteria attempt to attach
to the epithelial cells underlying the PCL. Once attached, the cells will trigger innate immune
responses, which can lead to initial inflammation processes [27]. After this, NTHi will try to
evade the immune response, using a series of enzymes to destroy antibodies, and its ability to
create microcolonies, and to invade the epithelial cells [26]. For this reason especially, NTHi is
an important pathogen to be aware of for treatment strategies.
The last of the historically major three bacteria associated with CF, Burkholderia cepacia is often
considered the most dangerous lung pathogen requiring rapid and rigorous medical attention.
Although first identified as an individual bacterial species related to Pseudomonas, it has since
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been reclassified as a complex of genomovars (Burkholderia cepacia Complex, BCC), which have
similar characteristics [28]. BCC is generally considered one of the main causes of pneumonia
in immunocompromised individuals, which includes CF patients. BCC has been found to co-
infect individuals with other CF associated bacteria, such as PA [29]. The complex is also known
to produce virulent factors, such as elastases and gelatinases, which can weaken cell-to-cell
interactions [29]. In addition, BCC fills a unique niche in the CF lung by being able to invade
macrophages that have made it to the lung. These tactics caused the bacterium to be of great
concern when it was first identified in CF patients in 1984, but since then, epidemiological and
clinical studies have greatly advanced treatment [28].
Several other genera of microbes, including Achromobacter, Pandorea, Alcaligenes, Stenotropho‐
monas, and Ralstonia, have also begun to be found in CF sputum in the past 20 years. These
bacteria are quite often associated with more advanced stages of the disease, indicating that
they may need the fertile ground of the CF lung to which they become accustomed before they
can thrive [19, 16]. Alcaligenes and Stenotrophomonas are increasingly found with a PA or BCC
infection [19]. In addition, several fungal pathogens have been associated with CF as well, such
as Aspergillus fumigatus and Candida albicans. While these fungi have not been the primary focus
of CF microbial treatment, recent evidence suggests that they can, in fact, become a problem
for CF patients. They have been associated with an increase in inflammation, as well as a
possibly more severe disease progression. Both host and fungal factors are equally important
in determining if the fungus will become pathogenic [30].
Although each of these pathogens has been studied as a single organism in the CF pathology,
limited efforts have been made into looking at the interaction between the bacteria. Consid‐
ering that more often than not multiple genera of bacteria are found in the CF lung, this is an
important aspect to consider. Research that has been studying this topic has focused generally
on the interaction between PA and another species of bacteria, as this is the most common
pathogen associated with CF. For instance, work has been conducted to elucidate the rela‐
tionship and interactions between PA and BCC. In these cases, initial reports showed that BCC
and PA formed communal biofilms, where both microbes could be detected in a “biofilm-like”
structure. They share similar quorum sensing molecules, and together could be promoting the
growth of one another. However, further investigation began to see that these bacteria did not
necessarily occupy the same biofilm structures [29]. In some cases, it could occur, and could
be recapitulated in vitro. However, in other situations, the bacteria did not cooperate. It seemed
that PA was producing a secreted chemical that prevented the growth of BCC nearby, which
was suspected to be pyocyanin [29]. This suggests that all of the relationships in CF may not
be symbiotic or even mutually beneficial. Perhaps it depends on the timeline of when the
infections are established. However, more work is needed to determine the actual relationship
between these bacteria. The entire web of bacterial networks in the CF lung is not trivial, but
deciphering how it works could potentially allow for more effective treatment of lung
infections.
While this paradigm of “the big three” bacteria for CF persisted for several decades, along with
the recent knowledge that several other species could infect the CF lung, a paradigm shift
occurred around 2008, when it was discovered that there were obligate anaerobes present in
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the lungs of older CF patients [31]. Included in this group of bacteria were the genera Prevotella,
Veillonella, Propionibacterium, and Actinomyces [31]. This indicated that at least part of the lung
must become anaerobic during the disease, which added to the notion that the CF lung has a
vast array of micro-environments within it, each of which can be colonized by different
bacterial species. It also corroborated the evidence of anaerobic niches being produced in the
mucus plugs, which to this point had only been associated with bacteria converting to
anaerobic growth.
With the discovery of the aforementioned anaerobic bacteria, it became clear that there was
most likely a temporal aspect of CF infections as well. Clinical evidence has shown that
depending on the age of the patient, certain bacteria are more likely to be cultured with their
sputum (Figure 3). Early in the patient’s life, from birth until around ten years of age, it is
common for patients to test positive for S. aureus; but later in life this infection seems to become
less likely [25]. PA can also be acquired early in life, however, much effort is often put into
trying to eliminate this infection. As a result, a patient may test positive for PA several times
throughout their life, even if the infections are not chronic. However, often by the patient’s
teenage years, PA has established a persistent infection and may have already converted to its
mucoid form [32], leading to 73% of adult CF patients harboring such an infection [33]. In
contrast to the “major” bacteria of CF, the newly discovered anaerobic bacteria generally do
not infect a patient until later in life. This is associated with the development of more anaerobic
niches in the lung, which is indicative of mucus buildup and thickening. This occurs later in
life as the detrimental effects of a defective CFTR build and the inflammation worsens.
Although treatment would still depend on cultures from the patients, establishing a general
timeline is beneficial for physicians who need to create a treatment plan for their patients, and
could allow for proactive treatment as the patient enters different phases of life.
Figure 3. Prevalence of respiratory microorganisms by age in 2013.
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As a CF patient progresses through life, the likelihood of culturing positive for a particular
microorganism changes. This is due mostly to the changing environment in the CF lungs. This
graph depicts the percentage of patients registered in the Cystic Fibrosis Foundation patient
registry who tested positive for a particular bacterium, separated by age [4].
Given the presence of anaerobic bacteria, this indicates that current antibiotic regimens for CF
patients may have to be revisited. Normal antibiotic treatments include tobramycin, kanamy‐
cin, and several other antibiotics of the aminoglycoside class. Those in this class are generally
ineffective against anaerobic bacteria due to their mechanism of entry. Aminoglycosides rely
on the ability of an organism to respire, using either nitrate or oxygen as the terminal oxygen
acceptor [34]. For fermenting bacteria, such as Actinomyces [35] and Prevotella [36], that means
that this class of antibiotics is ineffective. In the case of PA, the organism exists as a facultative
anaerobe that does use nitrate as a terminal oxygen acceptor. Although that should allow for
these antibiotics to work, reports are mixed on the efficacy of the treatment alone, noting the
ability for the bacteria to resist the action through a phenomenon termed “impermeability”
[37]. It has been observed in multiple studies that CF-related PA gains this ability, characterized
by a lack of uptake [37]. This may be related to the innate ability of PA to produce protective
biofilms in its mucoid state, a mechanism already shown to be protective against antibiotic
treatment. It may also be due to the action of certain genes involved in the biofilm formation,
as one study found that biofilms upregulated tolA, whose gene product can alter LPS structure
in such a way as to make it more resistant to aminoglycoside recognition, and bacteria which
did not produce as much of this protein were far more susceptible to aminoglycosides [38].
4. The major contributor: Pseudomonas aeruginosa
Perhaps the most problematic and dangerous of the bacteria associated with CF is PA. PA is a
gram-negative opportunistic pathogen that can sometimes be found as part of the normal
human skin flora. However, in cases where the immune system is compromised in some way,
the bacteria finds a way to infect a host, which can lead to severe complications. It is also
perhaps the most deadly bacteria to be associated with CF, as a patients life expectancy
decreases by roughly 7 years if the patient cultures positive for PA [37]. The reasoning for this
is that PA produces a large number of virulence factors that stimulate inflammation in the
airway, and often converts to a mucoid phenotype that allows it to escape a number of host
defenses and the use of many antibiotics.
4.1. The role of quorum sensing in PA infections
To control the expression of its virulence factors, PA uses a bacterial “communication” system
known as quorum sensing. This is not unique to PA, and has been shown to exist in a number
of other bacteria, including E. coli, S. pyogenes, and S. aureus (another CF associated bacteria)
[39]. However, much research has been conducted into the complex regulatory pathways
associated with this system in PA, which controls not only the means by which the bacteria
move in relation to each other, but also the expression of virulence factors that can affect the
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patient and the ability to convert into a biofilm [39]. Quorum sensing in PA is accomplished
by at least two regulatory pathways, the las and rhl systems [40]. The las system is hierarchically
first for sensing other molecules. The system is composed of two primary genes, lasR and
lasI, respectively. The transcriptional activator gene lasR, responds to environmental cues to
produce the transcription factor LasR. LasR on its own, however, cannot properly interact with
any genes. It needs a cofactor, specifically the quorum sensing autoinducer 3-oxo-C12-HSL
(PAI-1) produced by the lasI gene product. This molecule can be taken up from other nearby
bacteria that have released it into the supernatant and especially in biofilms [41]. When PAI-1
enters the bacteria, LasR forms a complex that is then able to act as a transcription factor. It
has two major targets in the system, lasI and rhlR. Importantly, by activating lasI, the system
begins an autoinduction loop that will maintain it in the cell and allow for the spread of signal
to other bacteria. The gene encodes an enzyme, LasI, which is able to produce the 3-oxo-C12-
HSL necessary to activate LasR. More active LasR results in the production of more LasI and
PAI-1, amplifying the signaling effect.
However, the system looping and increasing would mean nothing if there was not an output
somewhere. This output happens to be the second major system for quorum sensing, the rhl
system. This system behaves very similarly to the las system. After activation by the LasR-
PAI-1 complex, the RhlR transcription factor is produced. This requires a different signaling
molecule, C4-HSL (PAI-2), with which to form a complex. Once the initial signal is received,
the complex is formed and activates RhlI, which produces more PAI-2, and this, in turn,
perpetuates this signaling process. At the end of this process, the bacteria result in having a
buildup of RhlR-PAI-2 complex, which can help upregulate transcription of a number of
virulence factors, including lasA and lasB (elastase related enzymes necessary for invasion) [42,
40], xcpP and xcpR (components of the type II secretion system), and even the stationary phase
sigma factor gene rpoS, a gene linked to antibiotic resistance in PA [40]. However, one of the
most important secreted factors dependent on the rhl system is the production of rhamnolipids,
for which the system was named. These are important virulence factors that PA produces that
can lead to inflammation and associated immune responses.
Another important output of the las system is the Psedumonas quinolone signal (PQS) regulon.
The PQS regulon is responsible for some of the phenotypic changes seen with PA once it begins
to grow in communities [39, 40]. The regulon itself requires the induction of pqsR, the
regulatory transcription factor for the rest of the genes. Once this is active, the transcription
factor will homodimerize to activate the rest of the pqs genes, as well as the induction of
phenazine genes (phnAB). Together, these will allow for the production of HHQ (2-heptyl-4-
quinolone, a precursor to PQS) and PQS signals that will not only allow for the autoinduction
of the pathway, but also for the eventual production of pyocyanin and pyoverdin, important
siderophores that also lead to the green color that is often seen with PA-laden CF sputum. In
addition, this activates the production of Hydrogen Cyanide (HCN), an important metabolite
for PA as well as a potential toxic agent for the patient and other bacteria.
4.2. Alginate production and the conversion to mucoidy
Although these quorum-sensing pathways are important for the virulence associated with
PA, it is also important to note that this is not the only system involved in its infection of a CF
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patient. Perhaps more important for the chronic infection of patients are the genes and
pathways involved in the conversion of PA from its normal phenotype to its mucoid form.
This mucoid phenotype has been known to be associated with CF infection, especially during
chronic infection of patients [43, 31]. It is characterized by the general loss of motility for the
bacteria [44], and the overproduction of the viscous exopolysaccharide called alginate.
Alginate surrounds the bacteria and creates a material that seems quite like mucus, hence the
appropriate coining of the term “mucoid phenotype.” Mucoid PA has also been associated
with the production of biofilms and is involved in general resistance to several types of
antibiotics and environmental stresses, such as dessication and nutrient depletion. However,
this conversion is a complicated procedure that results in a signficantly altered regulatory
network of several genes associated with alginate production.
The most important gene involved in the process of alginate production is algU (algT), a major
component of the 12-gene operon that results in the production of alginate. AlgU is a extra-
cytoplasmic sigma factor that is expressed at a low level in nonmucoid bacteria, and this basal
level of protein is sequestered by the membrane spanning anti-sigma factor, MucA (Figure 4).
This interaction is very important for the eventual conversion to the mucoid state. When MucA
normally sequesters AlgU in its nonmucoid state, the bacteria do not produce any significant
amounts of alginate. However, under conditions of stress (oxidative, osmotic, heat shock), the
bacteria will eliminate MucA through one of two means [45]. The first is the proteolytic
destruction of MucA. In conditions where the bacteria are stressed due to nutrient depletion
(iron, carbon, or phosphorus), dessication, or antibiotics, the bacteria can trigger the produc‐
tion of a protease that targets MucA. Upon the degradation of this protein, the bound AlgU is
released into the cell to act as a sigma factor (σE,22), in combination with several other proteins,
to upregulate the operon responsible for alginate production, including most of the alg genes,
such as algD, algC, and many others. Once this is accomplished, the cell will produce and
secrete alginate, allowing for expression of the mucoid phenotype.
Under normal growth conditions in PA (Panel A), MucA (Blue) interacts with periplasmic
MucB (Green) to allow for cytosolic sequestering of AlgU (Red). This prevents AlgU from
acting as a transcription factor, effectively keeping mucoid genes inactivated. However, in
times of stress, PA can either inactivate MucA through proteolysis (Panel B) or hypermutation
(Panel C). In these cases, MucA is no longer able to interact with the periplasmic MucB, and
the result is the loss of sequestered AlgU, allowing it to now activate genes in the cell, including
AlgD and related mucoidy genes. Adapted from Hassett et al., 2009 [46].
However, in cases where constitutive mucoidy is found, such as in CF patients chronically
infected with PA, the phenotype is most often caused by a mutation within the mucA gene.
This is suspected to still be an outcome of environmental stress (as the CF lung is often lacking
water and may contain innate immune defenses). However, the result is not a temporary
upregulation of alginate related genes, but rather, a hypermutable phenotype that will usually
allow for mutations within the mucA gene to occur [45]. This hypermutability stems from the
mutation of several genes associated with DNA repair, including the DNA mismatch repair
system (MMR) and the deoxyguanine repair system (DO) [45], although errors from the DNA
polymerase IV could also lead to these mutations. The most common mutation found associ‐
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ated with this is in mucA. One such mutation, mucA22 (a deletion of 5 G residues from bases
431–436), is commonly found, although several others have been associated with this pheno‐
type. Because of these base deletions, the protein is truncated to 15.8 kDa, where it has lost its
binding domain for AlgU. As a result, AlgU is constitutively active in the bacteria, resulting
in a constant mucoid phenotype in vivo. A mucoid phenotype has also been associated with
mutations in other muc genes, including mucB, mucC, and mucD, however, these are not as
frequent.
Once the patient acquires mucoid PA, their clinical course usually diminishes dramatically.
This conversion is often a result of chronic PA infection, which may not cause a drastic change
in health immediately, but will cause chronic inflammation and lead to decreased lung
function. Currently, much of the effort for treating CF infections is focused on dealing with
biofilm associated bacteria, which includes the mucoid PA.
Figure 4. MucA interactions with AlgU.
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4.3. PA biofilm formation in CF patients
Herein, we will focus on the biofilm formation of PA on the biotic or abiotic surface, in vitro.
There are five steps for biofilm development on this kind of surface (Figure 5). This process
begins when (Step 1) the planktonic or free-living bacteria (Step 2) attach to the surface as show
in Figure 5. Several genes and factors are required for this initial step of biofilm formation such
as the expression of flagella, type IV pili, Cup fimbria, and the activation of sadB [47]. Next,
(Step 3) cells begin to produce the extracellular matrix components that facilitate the bacteria
joining together and forming microcolonies. The matrix contains polysaccharides, proteins and
eDNA, which plays a role in the up to 1,000-fold increase in antibiotic resistance of the biofilms
compared to planktonic bacteria cells [48, 49]. Then, (Step 4) the microcolonies will progress
and mature into a thicker biofilm (maturation), thus resulting in the development of a gradient
of oxygen in the biofilm. Here, the surface has a higher oxygen concentration than in the deeper
part of the biofilm. In this case, the biofilm is composed of aerobic, micro-aerobic, and anaerobic
environments. The factors that also play an important role in this maturation step are involved
cell motility. For example, the creation of the mushroom cap-like structure (biofilm maturation)
required pilA (a pilus component). This also involves parts of the quorum sensing system as
it has been shown that a lasI mutant will form a flat and thin biofilm while rhlI or pqsA mutant
form microcolonies lacking the mushroom caps [48]. Several genes have been reported to be
involved in the biofilm development such as the response regulator of the GacA/GacS two-
component regulatory system (gacA) that is involved with the extracellular matrix compo‐
nents, a sigma factor (rpoS) that regulates a number of genes in the stationary phase that overlap
with genes regulated by quorum sensing, the alginate biosysthesis regulator (algR) that is
involved in type IV-mediated twitching motility, and a regulator of exopolysaccharide and
Type III secretion (retS) [48, 50, 51, 52]. Finally, (Step 5) biofilm dispersion will occur where
the biofilm components have been broken down or modified to release the surface proteins
resulting in changes of the biofilm structure and also the forming of a new biofilm [47, 53].
Many genes have been studied in regard to biofilm dispersion. One such gene is rhlA, one of
the genes required for rhamnolipid biosysthesis, which has been reported to be required for
the dispersion of the bacteria from the center of the mushroom structure [54]. Another gene
involved is the biofilm dispersion locus (bdlA), which studies have shown may be a link
between sensing environment cues, c-di-GMP levels and detachment of the biofilm [52].
In CF patients, 65%–80% of all microbial infections are biofilm related [48]. The CF lung
provides a suitable environment for PA to infect and form a biofilm. The normal airway
epithelia cells are hydrated by a mucus that contains a mixture of electrolytes, glycoproteins
such as mucins, protein, and lipids. The failure to elucidate free-living PA by the inflammatory
system combined with the bacterial defense mechanisms such as oxidative stress in a CF
patient results in a vicious environment [55, 56]. This environment can be oxygen depleted as
well, causing it to be considered micro-aerobic or anaerobic [5]. Several studies have supported
the ability of PA to form a biofilm in the CF lung, such as one that used a microscopic study
of CF sputum, showing an increased resistance to antibiotics and phogocytosis because of the
higher production of EPS in the biofilm [46]. This is a common reason to initiate biofilm
development, as PA biofilms resist phagocytosis by immune cells and are also more resistant
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to antibiotics than a free-living cell [55]. To form a biofilm in the CF lung, PA must penetrate
the mucus layer and enter into a hypoxic zone, where it can then form a biofilm with a quick
transition from aerobic to anaerobic metabolism by using the alternative electron acceptors in
the mucus such as nitrate (NO3-), nitrite (NO2-) or nitrous oxide (N2O) through the respiratory
process known as “denitrification” to support anaerobic growth. The ability of PA to be able
to grow in the anaerobic condition is an important factor for the formation of biofilms in the
CF patient. PA also can use alginate as an energy source for anaerobic growth [48]. Finally,
these macrocolonies of PA are formed during a chronic infection of CF [53]. The summary of
the biofilm formation in CF patients is shown in Figure 6. Some of the important genes that
are involved in the denitrification system are nitrate reductase (nar), nitrite reductase (nir),
nitric oxide reductase (nor) and nitrous oxide reductase (nos). These genes are under tight
regulation in the chromosome. One gene that has been found to regulate this process, oprF, is
particularly important. It has been found that antibodies against this protein are elevated in
CF patients, suggesting that it is upregulated in the bacteria. In addition, an oprF null mutant
formed poor anaerobic biofilms due to no NIR activity [53]. Quorum sensing (QS) also
regulates the genes in the denitrification system. One study showed that rhl was required for
an optimum balance of the denitrification pathway [13].
4.4. Genetic alterations during PA infection
In addition to the changes that are phenotypically eminent such as during mucoid conversion,
it is also important to note that additional genetic regulation is occurring in this environment.
As mentioned earlier, the CF lung is not a hospitable environment for bacteria, due especially
to the dessicated mucus layer, yet it is quite nutrient-rich. If the bacteria can benefit from this,
then they will be able to survive and flourish in the lung. In order to do this, the bacteria must
undergo several layers of genetic regulation in order to activate specific shunt pathways that
will allow them to use the nutrients provided. In the case of PA, this has been studied exten‐
sively, but has required significant efforts to unravel, notably the creation of various synthetic
media that represents CF lung ASL [57] as close as anything else to date.
Figure 5. The five steps of Pseudomonas biofilm formation on a biotic or abiotic surface (in vitro).
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Early gene expression analyses showed several important changes in expression levels, but
suffered from lack of application. Some of the first analyses were of general biofilm gene
expression, which were important as a seminal work. For example, Whiteley et al. performed
a transcriptional profiling analysis in 2001 that examined gene expression by PA biofilms
grown on granite pebbles [38]. They discovered that only a small subset of genes showed any
change in expression (73 genes), roughly splitting 50:50 into up- and downregulated genes.
This was quite interesting, as considering the relatively large change in phenotype between
normal PA and biofilm structure, it would seem that more changes would have had to occur.
In addition, several genes promoting the resistance to certain antibiotics were upregulated,
and when they treated the biofilms with antibiotics, a different gene expression profile was
Figure 6. PA biofilm formation in the CF lung. A shows the normal epithelia cells. B–F depict CF airway epithelia. B–C
show the mucus formation as mentioned previously in the CF lung section of this chapter, resulting in the hypoxic
zones in the CF lung. D–F illustrate the free-living cell bacteria moving into the hypoxic area (D). E shows the bacteria
adjusting themselves from an aerobic to anaerobic condition and forming macrocolony, biofilm, in this environment. F
shows the increasing amount of macrocolonies.
An Overview of Infections in Cystic Fibrosis Airways and the Role of Environmental Conditions on…
http://dx.doi.org/10.5772/60897
187
seen. This all suggested that biofilm bacteria might be able to respond better to antibiotics and
environmental stresses than planktonic cells, as the biofilm is not only more inherently
resistant, but the bacteria interior to the film experience a lower concentration of the stressor,
allowing for genetic regulations and responses [38]. Following this paper, more attempts to
analyze biofilm-related genes ensued. These studies involved mostly environmental biofilms,
and not those associated with human infection. Eventually, as the prevalence of biofilms in
disease became better known, it became important to discover if these changes in biofilm gene
regulation were able to be transitioned over to this situation.
In this regard, several attempts to examine human-associated biofilm infections occurred, but
it had to be verified that the gene expression difference was reliable, and not an artifact of the
harvesting procedure. Some studies did well with this issue, collecting PA from patients and
analyzing both that sample and in vitro grown cells. These differences did seem quite signif‐
icant, showing changes between the two samples that suggested a decrease in the regulatory
machinery for biofilm cells rather than an upregulation of many of the biofilm associated genes
(such as muc, alg, rhl, hcn, and plc) [58]. This was novel, as the biofilm conversion seemed much
more complicated than simply via a dysregulatory pathway.
Other genes that were found to be changed in the CF lung associated samples seemed to
actually be associated with the acquisition of nutrients in the surrounding area. For example,
one such study found that there was an increase in genes associated with arginine metabolism
and the glyoxylate shunt (a process found often with the β-oxidation of lipids to acetyl-CoA)
[59]. This seems to indicate that the CF lung has a higher available amount of arginine and free
lipids for degradation, potentially linked to the death of epithelial cells in the lung. This same
study also found the cells generally change to a sessile state, where many of the genes
associated with motility and chemotaxis are downregulated. This indicates that the cells
initially colonizing the CF lung are able to prosper enough that the organisms can rapidly
adapt to such conditions. This same down-regulation of motility genes is often seen with the
conversion to a biofilm mode of growth. Once the bacteria have shifted to the mucoid state
and are able to survive the thick, dessicated mucus, then they will be able to thrive in the lung.
This can help explain why PA is often such a major problem for the CF patients.
5. Treatment strategies for CF
Considering the relative abundance of CF cases (~70,000 world-wide), it is important that
efforts are put forward into treating the symptoms that arise from the disease [60]. These
symptoms can be very detrimental, especially in the case of serious bacterial infections and
ensuing exacerbations. Initially, the treatments that were available were only focused on chest
physical therapy for the buildup of airway mucus, but those efforts have evolved as current
research has illuminated more on the pathophysiology of CF lung disease. An example of
advanced treatment with continuing research was the initial attempts to provide gene therapy
for CF. With the idea that complementing the mutated CFTR with wild-type CFTR would
allow for functional ion transport, efforts were made to transfect cells with a functional copy
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of the gene using either a liposomal or viral vector. However, this eventually ended in failure,
as the complementation strategy was unsuccessful and in some cases harmful. Specifically,
adenovirus complementation caused a hyper-immune response, and DNA liposome trans‐
fection could not properly deliver the DNA to the nucleus [61]. Recent attempts are examining
whether transfecting cells with mRNA coding for functional CFTR could be beneficial.
However, this still requires much more research. With that in mind, treatment falls primarily
into two main camps; the removal of the dessicated mucus, and the treatment of bacterial
infections.
5.1. Treatment of mucus buildup
Even without the involvement of pathogens in the mucus plugs that develop in the CF lung,
the plugs themselves can cause serious effects on the patients, specifically in their quality of
life. As mentioned previously, these plugs develop from a lack of clearance of mucus associated
with the pericilliary layer, resulting in a continually developing blockage and a decreased
airflow that reaches the respiratory zone of the lungs. With reduced oxygen levels, the patients
begin to suffer and can eventually become cyanotic. However, this is one of the more apparent
symptoms of CF, and has been a focus since the disease was first identified. Here, the primary
mode of treatment has been physical percussion of the patient. This is termed as chest physical
therapy (CPT) and has progressed much since it was initially developed. This treatment
initially involved pounding on the patient’s back in such a manner as to dislodge mucus that
was clinging to the bronchi [62]. After dislodging the mucus, the patient would then cough up
any that was loosened, but this process in general was quite painful and not desired by patients,
even when it was successful. In an effort to make this a more effective procedure, technology
began to be introduced into the process. Initially, a device similar to a back-pack, was created
that performed the percussion automatically, rather than rely on the doctor or medical
professional. Although this is effective in providing the same amount of force each time, the
percussion itself was not eliminated from the process.
Following this, different methods were employed to physically break up the mucus. These
have become more advanced in recent decades. Most are reliant on sound waves or vibrations
to loosen the mucus that allows for its eventual clearance. These methods include masks and
vests that patients don that create vibrations and devices that convert the exhaled air of a
patient into vibrations [62]. In all of these, the pressure and pain of physical percussion is
eliminated, but the positive effects remain. Even some chemical treatments are prescribed to
help loosen the mucus, such as aerosolized sodium bicarbonate that can help return the mucus
layer to its normal pH and allow for better clearance. Physicians also routinely prescribe
bronchodilators and anti-inflammatory medications to patients to both increase the functional
airway passage and to help clear some of the mucus from the airways. In some extreme cases,
where this use of medication is ineffective or does not keep up with the overall progression of
the disease, the patients may have to endure a lung transplant [62]. While this is occasionally
effective, it usually results in the eventual buildup of mucus in the lungs once again, resulting
in further treatment or potentially even another transplant.
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5.2. Treatment of bacterial infections
While the buildup of mucus within the lungs is quite problematic, it is often not what leads to
the overall mortality or morbidity of CF patients. Rather, this is due to secondary infections
that arise from this buildup. As stated earlier, this mucus is a rich, largely immobile niche of
complex nutrients that enmesh the bacteria. In healthy lungs, the cilia are functioning properly
with a thin PCL and clearing most pathogens out of the lungs. However, with the thick mucus,
this is not the case, as the cilia do not have enough physical force to push it upwards. As a
result, bacteria begin to infect the area. However, the precise location in the lungs where the
infection resides is important for the choice of treatment methods. In general, the lungs are
divided into two zones. The first is the conductive zone, which includes many of the prelimi‐
nary branches of the bronchi and does not directly include the alveoli or any of the accompa‐
nying areas. The second is the respiratory zone, which includes many of the later branches of
the airways and the alveoli. These differences are important due to the necessary changes for
treatments. In the conductive zone, the tissue does not have quite as high a vascular exposure,
but is much closer to the mouth. As such, infections in this area are often treated with aero‐
solized medicines. In contrast, the respiratory zone is much deeper into the lungs, but has
much higher vascular exposure due to the presence of the alveoli in this zone. Treatments for
this zone usually include oral or intravenous medications. While the mode of treatment is
known, the actual ability to determine where the infection is occurring is dependent on a series
of initial cultures from the patient, and the species present can change once treatment begins.
Once the type of treatment has been determined, the next step is determining what the effective
antibiotic(s) is for the particular bacteria being targeted. This is dependent on the class of
antibiotic and has to be administered in a patient-specific manner. In general, there are some
that work more efficiently in certain patients than in others. For example, tobramycin, a potent
aminoglycoside, has been approved by the FDA for clinical treatment of PA in CF patients.
However, various reports have shown an impenetrability of tobramycin in biofilms, an effect
that may be due to the lowered levels of oxygen within the biofilms. The ability of an antibiotic
to be active on biofilm bacteria is of the utmost importance when selecting a treatment strategy
[33]. As mentioned previously, biofilms generally develop more resistance to certain antibi‐
otics due to their differential metabolism, as well as penetration issues. Those at the surface of
the biofilm are generally more metabolically active, while those in the middle of the biofilm
projections and those at the base are generally far less active or even inactive. Ciofu et al. [63]
showed that certain antibiotics will be more or less effective in these areas depending on their
mode of action. Tobramycin is highly effective on the more oxygen-rich outer layer of
metabolically active bacteria, but others such as colistin are better suited at dealing with the
metabolically inactive bacteria further into the biofilm. In addition, both basic and clinical
scientists are focusing better on the proper physiology of bacteria for treatment. This is
something that is case-dependent, and cannot necessarily be generalized.
However, the efficiency of the antibiotics for long-term treatment of PA infections has been
worrisome, especially because of the development of multi-drug resistant PA (MRPA) [64].
Because of these issues, it is imperative to unravel new treatments that will work on bacteria
that are growing under non-traditional conditions (e.g., anaerobic or microaerobic). That is
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why certain groups are evaluating the ability of other compounds for bactericidal action. One
of the more notable treatments was discovered by our group in defining the use of acidified
nitrite for the treatment of mucoid PA infections. In 2006, we discovered that the application
of acidified nitrite onto anaerobic PA, both planktonic and biofilm associated, virtually killed
the organisms; however, the same effect was not quite seen aerobically [65]. The treatment also
had to be administered at a slightly acidic pH (6.5) of the CF lung. This combination, however,
was very effective. Further investigation showed that acidified nitrite was unstable and
produced a toxic, bactericidal intermediate nitric oxide (NO). Although PA normally proceeds
through the route of denitrification, this process is overloaded by an excess of NO2-, and
subsequently NO. The enzymes involved in the detoxification process are not able to com‐
pensate for this overload, and the bacteria ultimately become poisoned. This occurs through
the reaction of NO with sulfur from cysteines in the proteins in the cell, which produces S-
nitrosylated proteins (S-NO) that are targeted for degradation. In addition, NO also reacts with
iron/heme containing proteins leading to the formation of dinitrosyl iron complexes. Consid‐
ering the simplicity and remarkable efficacy of this treatment, this is an example of what to
look for in the future.
6. Future treatments
While advancements in medicine are not written in stone, there are trends that are observable
that can dictate what advancements should be expected. Most of these trends are collected on
the website for the CF Foundation [66], which monitors all forms of data related to CF research.
In this case, they maintain a log of what is in the pipeline for research, as well as commonly
available treatments for patients. In general, the medications available fall into six categories:
CFTR modulators, anti-inflammatory drugs, anti-infective drugs, nutrition, mucus alteration,
and airway surface restoration. Much of the research on medications has been focused on anti-
inflammatory and anti-infective medications. While most of the anti-infective compounds
have been modifications of available antibiotics into inhalable forms (such as aerosolized
amikacin and vancomycin), the developments in anti-inflammatory medications are slightly
more unique. One such example is the development of a drug that is targeting the Type III
Secretion System of PA. This is a humanized monoclonal antibody directed against one of the
protein components of the T3SS. The study states that its goal is to develop an anti-inflamma‐
tory molecule, which this antibody serves to do. By interacting with the T3SS, it will hopefully
reduce any inflammation caused by sensing this molecule, and potentially reduce the amount
of molecules secreted by this system. However, as they note, this is not a means to kill PA [66].
The antibody does not serve that purpose, so it is not able to function as an antibiotic in infected
patients.
Another field that seems to be growing with potential treatments is the area of CFTR modu‐
lators. This field of treatment is focused on finding drugs that change the defective behavior
of mutant CFTR protein. Since one form of mutant CFTR is produced yet does not make it to
the apical membrane of the cells, some thought has gone into making it possible for the protein
to make it to the surface, and hopefully in that process, fold properly to allow for a functioning
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anion channel. All of these are experimental compounds, but have made it to Phase 2 clinical
trials at the time of this publication [66]. The first is a “potentiator”, a compound that suppos‐
edly will be able to open a defective CFTR once it has reached the surface. While this is not
meant for all forms of the disease, it is possible that this will have a great impact. Next is a
“corrector” that is meant to move the folded protein to the correct location in the cell. This can
help with proteins that have misfolded and are sent for degradation or are sent to a different
membrane of the cell (e.g., basolateral). Finally, a synthetic signaling molecule has been
developed that is meant to supplement decreased levels of S-nitrosoglutathione (an NO
generator) in the cells of CF patients. This signaling molecule has been found to be decreased
in these patients, and already evidence from the trial has shown that by supplementing this
signal, there is increased and proper folding of the CFTR and function of the channel once it
is in the membrane.
7. Conclusions
Bacterial infections of CF patients have been a cornerstone of treatment for decades, and that
will not change going forward. Future efforts will be focused on finding alternative treatments
that will be able to affect both planktonic and biofilm associated organisms in the lungs. This
aspect of bacterial growth is most likely the key to effectively remove the organisms from the
CF lung and improve the overall life expectancy for these patients. Already, great advances
have been made in the last thirty years, as evidenced by not only the number of new and
varying treatments, but also by the increased average life span for CF patients (40.7 years) [4].
While some research will still be focused on finding a way to directly treat the CFTR mutation,
short-term research needs to be focused on discovering new and innovative treatment options.
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